映恩生物-B(09606.HK) 公布,公司核心产品DB-1303/BNT323基于III期关键临床研究所获得的积极结果,以及与国家药监局药品审评中心的新药上市申请前沟通交流反馈,提交的生物制品新药上市申请已获国家药品监督管理局受理。III期临床试验旨在评估DB-1303相较于T-DM1在既往接受曲妥珠单抗和紫杉烷类治疗的HER2阳性不可切除或转移性乳腺癌患者中的疗效和安全性。(de/d)(港股...
Source Link映恩生物-B(09606.HK) 公布,公司核心产品DB-1303/BNT323基于III期关键临床研究所获得的积极结果,以及与国家药监局药品审评中心的新药上市申请前沟通交流反馈,提交的生物制品新药上市申请已获国家药品监督管理局受理。III期临床试验旨在评估DB-1303相较于T-DM1在既往接受曲妥珠单抗和紫杉烷类治疗的HER2阳性不可切除或转移性乳腺癌患者中的疗效和安全性。(de/d)(港股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.